Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- NCC, 5 Other Institutions Forge Genome Cohort of 366,000 People
May 28, 2021
- Hematologist Sees No Swelling Costs from 2 New CAR-T Contenders in Japan; Will Competition Drive Down Prices?
May 28, 2021
- New AMR Prevention Technology Could Contribute to Antiviral Development; Application to COVID-19 Meds Expected: Professor
May 17, 2021
- Olumiant Expected to Shorten Time to Recovery from COVID-19: Infection Expert
May 12, 2021
- No. of New Lung Cancer Patients Fell 6.6% in 2020 amid COVID-19: Survey
May 11, 2021
- Survival Rate Declines for Some Cancers Even after 5 Years: NCC
April 28, 2021
- New RA Guidelines Upgrade Position of JAK Inhibitors, Biosimilars on Equal Footing with Reference Products
April 26, 2021
- Tokushukai Weighs Switches from Nichi-Iko Products after Biz Suspension Order
March 15, 2021
- COVID-19 Vaccination Should Be Avoided in Patients with Severe Hypersensitivity to PEG: Allergy Society
March 3, 2021
- Thorough Medication Guidance through Regional Collaboration Important for Rybelsus: Professor
February 22, 2021
- NCGM to Initiate Clinical Study of Convalescent Plasma Therapy for COVID-19 as Early as February
January 28, 2021
- Lynparza Got Prostate Cancer OK, but Reimbursement Issues Remain for CDx Costs: Professor
January 22, 2021
- Antitussive Cloperastine Strongly Attacks Cisplatin-Resistant Cancer Cells: Research Group
January 22, 2021
- Japan Reports Mother-to-Infant Cervical Tumor Transmission via Amniotic Fluids
January 7, 2021
- NCGM, Fujita Univ. to Join NIH’s Immunoglobulin Trial for COVID-19
December 24, 2020
- Alvesco Fails in COVID-19 Trial, NCGM Says It Can’t Be Recommended
December 24, 2020
- 4 Scientific Societies Call for COVID-19 Vaccine Recipient Registry
November 30, 2020
- Chugai’s Multigene Panel Test Difficult to Use as CDx, Reimbursement Rules Should Be Revised: KOL
November 25, 2020
- 5-Year Cancer Survival Rate at 68.6%, Largely Unchanged: NCC
November 24, 2020
- National Cancer Center Exploring Effectiveness of Frontline Use of Multigene Panel Testing for Solid Tumors
November 18, 2020
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…